Gonzalez-Serna, AFerrando-Martinez, STarancon-Diez, LDe Pablo-Bernal, R SDominguez-Molina, BJiménez, J LMuñoz-Fernández, M ÁLeal, MRuiz-Mateos, E2023-01-252023-01-252017-12-20http://hdl.handle.net/10668/11929NRTIs-sparing regimens exert favourable profiles on T-cell homeostasis associated parameters. Our aim was to analyze the effect of NRTIs sparing regimen (NRTI-sparing-cART) vs NRTIs-containing regimen (NRTI-cART), on T-cell homeostasis associated parameters in naive HIV-infected patients. Biomarkers of cell survival (CD127) and replicative senescence (CD57), were measured by multiparametric flow cytometry for T-cell phenotyping on peripheral blood mononuclear cells (PBMCs) samples just before (baseline) and after 48 weeks of undetectable viral load in patients on NRTI-sparing-cART (N = 13) and NRTI-cART (N = 14). After 48 weeks a subgroup of patients (n = 5) on NRTI-cART switched to NRTI-sparing-cART for another additional 48 weeks. In vitro assays were performed on PBMCs from HIV-uninfected healthy donors exposed or not to HIV. To analyze the independent factors associated with type of cART bivariate and stepwise multivariate analysis were performed after adjusting for basal CD4+, CD8+ and nadir CD4+ T-cell counts. After 48 weeks of a NRTI-sparing-cART vs NRTI-cART patients have higher effector memory (EM) CD4+ CD127+ T-cell levels, lower EM CD4+ CD57+ T-cell levels, higher CD8+ CD127+ T-cell levels, lower CD8+ CD57+ T-cell levels and higher memory CD8+ T-cell levels. This effect was confirmed in the subgroup of patients who switched to NRTI-sparing-cART. In vitro assays confirmed that the deleterious effect of a NRTIs-containing regimen was due to NRTIs. The implementation of NRTI-sparing regimens, with a favourable profile in CD127 and CD57 T-cell expression, could benefit cART-patients. These results could have potential implications in a decrease in the number of Non-AIDS events.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/CD127CD57HIVNRTI-sparingAdultCD57 AntigensDrug Therapy, CombinationFemaleHIV InfectionsHomeostasisHumansInterleukin-7 Receptor alpha SubunitMaleMiddle AgedReverse Transcriptase InhibitorsT-Lymphocytesresearch article29262860open access10.1186/s12967-017-1367-51479-5876PMC5738860https://doi.org/10.1186/s12967-017-1367-5https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738860/pdf